^○Takahiko Saida^1,2,4, Qi Hao^1,2,4, Michiko Yamauchi^1,4, Kyoko Saida^1,2,3,4 (1.Kansai Multiple Sclerosis Center, Japan, 2.Irino Clinic, Japan, 3.Kyoto-Hakuaikai Hospital, Dept. of Neurology, 4.Institute of Multiple Sclerosis Therapeutics, Japan)

^○Yuko Kobayakawa^1,2, Koji Todaka², Yu Hashimoto¹, Ryo Yamasaki¹, Jun-ichi Kira^3,4,5 (1.Department of Neurology neurological Institute, Graduate school of Medicine, Kyushu University, Japan, 2.Kyushu University, Center for Clinical and Translational Research, Japan, 3.Translational Neuroscience Center, Graduate School of Medicine, International University of Health and Welfare, 4.School of Pharmacy at Fukuoka, International University of Health and Welfare, 5.Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare,)

^○Fumihiko Sakai¹, Sunfa Cheng², Noboru Imai³, Takao Takeshima⁴, Koichi Hirata⁵, Yasuhiko Matsumori⁶, Yoshihisa Tatsuoka⁷, Yotaro Numachi⁸, Peng Peng⁹, Daniel D. Mikol² (1.Saitama International Headache Center, Japan, 2.Global Development, Amgen Inc., 3.Department of Neurology, Japanese Red Cross Shizuoka Hospital, 4.Headache Center, Department of Neurology, Tominaga Hospital, 5.Headache Center, Department of Neurology, Dokkyo Medical University, 6.Sendai Headache and Neurology Clinic, 7.Department of Neurology, Tatsuoka Neurology Clinic, 8.Research & Development, Amgen K.K., 9.Global Biostatistical Science, Amgen Inc.)

^○Yasuhiko Matsumori¹, Tomomi Nakamura², Akichika Ozeki², Holland C. Detke³ (1.Sendai Headache and Neurology Clinic, Japan, 2.Eli Lilly Japan K.K., 3.Eli Lilly and Company)

^○Tomohide Adachi¹, David Kuter², Siobán Keel³, Charles Parker⁴, David C. Rees⁵, Ulrich Stölzel⁶, Paolo Ventura⁷, Manisha Balwani⁸, Laurent Gouya⁹, Amy Simon¹⁰, Shangbin Liu¹⁰, John Ko¹⁰, Sean Rhyee¹⁰, Samuel Silver¹¹ (1.General Internal medicine and Neurology, Tokyo Saiseikai central Hospital, Japan, 2.Massachusetts General Hospital, Boston, Massachusetts, USA;, 3.University of Washington, Seattle, Washington, USA, 4.University of Utah, Salt Lake City, Utah, USA, 5.King's College Hospital, United Kingdom, 6.Klinikum Chemnitz, Chemnitz, Germany, 7.Università degli Studi di Modena e Reggio Emilia, Modena, Italy, 8.Icahn School of Medicine at Mt. Sinai, New York, New York, USA, 9.Centre Français des Porphyries, Paris, France, 10.Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA, 11.University of Michigan, Ann Arbor, Michigan, USA)

^○Yasuhiro Takeshima¹, Basil T Darras^2,5,8, Riccardo Masson³, Maria Mazurkiewicz-beldzinska⁴, Kristy Rose⁵, Hui Xiong⁶, Edmar Zanoteli⁷, Angela Dodman⁸, Muna El-khairi⁸, Marianne Gerber⁸, Ksenija Gorni⁸, Heidemarie Kletzl⁸, Renata S Scalco⁸, Laurent Servais⁹ (1.Department of Pediatrics, Hyogo College of Medicine, Hyogo, Japan, 2.Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, 3.Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy, 4.Department of Developmental Neurology Medical University of Gdansk, Gdansk, Poland, 5.Paediatric Gait Analysis Service of New South Wales, The Children's Hospital at Westmead, Sydney, Australia, 6.Department of Pediatrics, Peking University First Hospital, Beijing, China, 7.Department of Neurology, Faculdade de Medicina, Universidade de São Paulo (FMUSP), São Paulo, Brazil, 8.F. Hoffmann-La Roche Ltd, Basel, Switzerland, 9.MDUK Oxford Neuromuscular Center, Department of Paediatrics, University of Oxford, Oxford, UK)